ClinicalTrials.gg
Active, not recruitingNCT05363800Updated Jun 5, 2026

Phase I Study of HRS-3738 in Recurrent and Refractory Non-Hodgkin's Lymphoma and Multiple Myeloma

A Phase 1 interventional study of HRS-3738 in Recurrent and Refractory Non-Hodgkin's Lymphoma and Multiple Myeloma, sponsored by Jiangsu HengRui Medicine Co., Ltd.. Active, not recruiting at 3 sites in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-06-05.

Primary conditionLymphoma, Non-HodgkinRegistry: RecurrenceReclassifiedWhy we changed it
Registry
Recurrence — the first condition term the registry derived for this study.
ClinicalTrials.gg
Lymphoma, Non-Hodgkin
Why
  1. Recurrence describes something many studies share rather than a condition a study is about.
  2. The study's listed conditions name Lymphoma, Non-Hodgkin.
Confidence
High: the new condition is named in the study's own listed conditions. Of 351 hand-checked studies reclassified this way, 68% were exactly right and 84% in the right disease family; the registry's first term was right for 5% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by Jiangsu HengRui Medicine Co., Ltd. · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
74
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 196 studies in Lymphoma, Non-Hodgkin with a site in China — 83 open to participants now, 110 under way, 14 of them phase 3. Lymphoma, Non-Hodgkin · China.

Enrollment
73rd of 183
74 · median 58
Started
2022
with 27 others
Phase 1
79 of 196
33 open now
Primary completion
2026-12
later than 53 of 109 live
Registered
115th of 196
by date

Among the 196 studies in Lymphoma, Non-Hodgkin with a site in China, this one is the 73rd largest by enrollment of the 183 interventional ones that give a count, is one of 28 that started in 2022, is one of 79 in phase 1, reaches primary completion later than 53 of the 109 other live ones, and was the 115th registered.

Lymphoma, Non-Hodgkin

2,288 studies on the registry are indexed under Lymphoma, Non-Hodgkin; 286 are open to participants now.

Browse Lymphoma, Non-Hodgkin studies →

Open to participants now

83 of the 196 studies in Lymphoma, Non-Hodgkin with a site in China are open now. Recruiting first, the newest first:

78 more — sign in →

All 83 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 245 Lymphoma, Non-Hodgkin studies recruiting now, 145 (59%) set no upper age limit and 77 (31%) stop at 75 or younger; 68 take children under 18; 10 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 196 studies in Lymphoma, Non-Hodgkin with a site in China, or all of them as a file.
02

Study summary

This study is an open-label, multicenter Phase I clinical trial to evaluate the safety, tolerability, pharmacokinetics and efficacy of HRS-3738 in patients with recurrent and refractory Non-Hodgkin's lymphoma and multiple myeloma.

03

Conditions studied

  • Recurrent and Refractory Non-Hodgkin's Lymphoma and Multiple Myeloma

Browse trials for

04

In context

Lymphoma, Non-Hodgkin Reclassified

2,288 studies on the registry are indexed under Lymphoma, Non-Hodgkin; 286 are open to participants now.

This study's enrollment of 74 is above the median of 40 across 1,883 interventional studies indexed under Lymphoma, Non-Hodgkin.

Browse Lymphoma, Non-Hodgkin studies →

Lead sponsor

Jiangsu HengRui Medicine Co., Ltd. is the lead sponsor of 573 studies on the registry; 88 are open to participants now.

Of its 10 completed or terminated interventional studies of FDA-regulated products, 1 (10%) have results posted.

Compared within Lymphoma, Non-Hodgkin, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Recurrence. The counts are of registry records indexed under each term, refreshed daily. How we classify →

05

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Active multiple myeloma in accordance with IMWG criteria,or histopathologically and immunohistochemically confirmed non-Hodgkin's lymphoma in accordance with the 2016 WHO Classification of lymphoid neoplasias.
  2. Recurred or did not alleviate after the previous treatment.
  3. Have at least one .
  4. With a of ≥3 months.
  5. Male or female ≥ 18 years old.
  6. performance status of 0-1.
  7. Subjects must voluntarily agree to participate in the trial and sign a written form.

Exclusion criteria

Exclusion Criteria:

  1. Amyloidosis, plasma cell leukemia.
  2. Corrected serum calcium>3.4mmol/L(13.5mg/dl).
  3. Presence of to central nervous system.
  4. Treatment of other products.
  5. Major surgical therapy within 28 days prior to the date of signature of form, or expected major surgery during the study.
  6. Known history of to any components of HRS-3738.
  7. Other factors that may affect the study results or lead to forced termination of the study early as judged by investigators.
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

06

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
74 participants (actual)

Study arms

  • Experimental
    HRS-3738

    In dose Escalation: HRS-3738 will be taken in oral. Seven dose levels are preset. In dose Expansion: 2 to 3 dose cohorts will be selected for dose expansion stage. In indication Expansion: Indications will be selected to evaluate preliminary efficacy.

    Drug: HRS-3738

Interventions

  • DrugHRS-3738

    HRS-3738 will be administrated per dose level in which the patients are assigned.

07

What researchers measure

Primary outcomes

  1. Maximum tolerated dose (MTD)

    Incidence and category of dose limiting toxicities (DLTs) during the first 28-day cycle of HRS-3738 treatment.

    Time frame: From Day 1 to Day 28

  2. RP2D

    RP2D will be determined on the basis of evaluation on safety, PK, efficacy data in dose escalation and dose expansion stages.

    Time frame: From Day 1 to Day 28

Secondary outcomes

  1. Safety endpoints: adverse events(AEs), serious adverse events(SAEs)

    Assess safety and tolerability of HRS-3738 by way of adverse events (CTCAE v5.0).

    Time frame: From Day 1 to 30 days after last dose.

  2. Efficacy endpoints: Overall response rate (ORR)

    Evaluated using Lugano 2014 criteria and IMWG criteria.

    Time frame: From Day 1 to 30 days after last dose.

  3. Efficacy endpoints: Best of response (BOR)

    Evaluated using Lugano 2014 criteria and IMWG criteria

    Time frame: From Day 1 to 30 days after last dose

  4. Efficacy endpoints: time to response (TTR)

    Evaluated using Lugano 2014 criteria and IMWG criteria.

    Time frame: From Day 1 to 30 days after last dose.

  5. Efficacy endpoints: Duration of response (DoR)

    Evaluated using Lugano 2014 criteria and IMWG criteria

    Time frame: From Day 1 to 30 days after last dose

  6. Efficacy endpoints: Progression-free survival (PFS)

    Evaluated using Lugano 2014 criteria and IMWG criteria

    Time frame: From Day 1 to 30 days after last dose

  7. Efficacy endpoints: overall survival (OS).

    Evaluated using Lugano 2014 criteria and IMWG criteria.

    Time frame: From Day 1 to 30 days after last dose.

  8. Cmax

    Maximal plasma concentration

    Time frame: From Day 1 to 30 days after last dose

  9. Tmax

    Time to Cmax

    Time frame: From Day 1 to 30 days after last dose

  10. AUC

    Area under the plasma concentration-time curve

    Time frame: From Day 1 to 30 days after last dose

  11. t1/2

    Terminal-phase elimination half-life

    Time frame: From Day 1 to 30 days after last dose

  12. Vz/F

    Apparent volume of distribution during terminal phase after non-intravenous administration

    Time frame: From Day 1 to 30 days after last dose

  13. CL/F

    Apparent total clearance of the drug from plasma after oral administration.

    Time frame: From Day 1 to 30 days after last dose

08

Study locations

3 sites
  • Henan cancer Hospital
    Zhengzhou, Henan 450000, China
  • Sheng Jing Hospital of China Medical University
    Shengyang, Liaoning 110004, China
  • Zhejiang University School of Medicine The First Affiliated Hospital
    Hangzhou, Zhejiang 310003, China
09

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jun 2022 (actual). Primary completion is estimated for Dec 2026, 54 months after the start.

Of 163 industry-sponsored phase 1 interventional studies under Lymphoma, Non-Hodgkin, half reached primary completion within 47 months of starting (the median), counting those still running; a quarter within 37 and three quarters within 70. This study's planned 54 months is above that.

Counting every sponsor, half of 286 studies reached it within 55 months; a quarter within 38 and three quarters within 75.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 25, 2022
First posted
May 6, 2022
StartActual
Jun 17, 2022
Primary completionEst.
Dec 30, 2026
CompletionEst.
Dec 30, 2026
Last update
Jun 5, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 5, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT05363800
Responsible party
Sponsor
First posted
May 6, 2022
Start date
Jun 17, 2022
Primary completion
Dec 30, 2026 (estimated)
Completion
Dec 30, 2026 (estimated)
Last update
Jun 5, 2026

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Jun 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion